|Bid||0.00 x 34700|
|Ask||0.00 x 29800|
|Day's range||2,720.00 - 2,772.00|
|52-week range||1,636.00 - 2,840.00|
|PE ratio (TTM)||59.13|
|Earnings date||20 Feb 2017 - 24 Feb 2017|
|Forward dividend & yield||0.23 (0.81%)|
|1y target est||2,595.29|
Dechra Pharmaceuticals PLC, LSE: Main Market: symbol DPH) today releases its Half-Yearly Financial Report 2018 for the six months ended 31 December 2017 (the Period). "Dechra has performed well in the Period with solid revenue growth in EU pharmaceuticals and strong revenue growth in NA Pharmaceuticals from the existing business. Current trading continues in line with management expectations and the initial phase of integration of the AST Farma/Le Vet acquisition is progressing well.
(Reuters) - Veterinary firm Dechra Pharmaceuticals Plc (DPH.L) said it would buy the Netherlands-based AST Farma and Europe-focused Le Vet for 340 million euros (296.79 million pounds) in a cash and share ...